“During the first quarter and over recent weeks, our teams have been working diligently to close out the global BEACON-IPF trial with the goal of announcing topline data in the second quarter,” said Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant. “Additionally, progress was made in our oncology program with initial data from our Phase 1 dose escalation trial of PLN-101095 demonstrating antitumor activity, including confirmed partial responses, in a variety of solid tumors.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLRX:
- Pliant Therapeutics reports Q1 EPS (92c), consensus (75c)
- Pliant Therapeutics to reduce workforce by 45%
- Pliant Therapeutics Announces Major Workforce Reduction
- Hold Rating on Pliant Therapeutics Amid Uncertainty and Limited Data from Early-Stage Trials
- Neutral Rating on Pliant Therapeutics Amid Early Promising Data and Uncertainties